Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025

Beyond the bone marrow: a review of therapeutic approaches for extramedullary disease in multiple myeloma and the significance of MRD assessment.

View Full Paper
Ask AI
Bookmark
Share

Authors

DDDaniela DiaconescuDSDan-Sebastian SOARECMCristina Marinescu

Discussion

Loading...

Member takes

Overview

This review highlights therapeutic approaches for extramedullary disease in multiple myeloma, emphasizing MRD assessment for prognosis.

Key Points

  • Extramedullary disease is associated with poor prognosis and requires individualized treatment strategies.
  • Therapies include systemic treatments like proteasome inhibitors and advanced options like CAR-T and bispecific antibodies.
  • Diagnostic strategies rely on imaging techniques such as PET-CT and the importance of MRD monitoring is stressed.
  • A multidisciplinary approach is crucial for diagnosis and treatment optimization, along with the need for EMD-specific clinical trials.

Cite This Study

Diaconescu et al. (2025) studied this question.

synapsesocial.com/papers/68c24126b210217d6479e485https://doi.org/10.25122/jml-2025-0104
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Therapeutic options for extramedullary involvement in multiple myeloma2025
  2. 2Spatially resolved transcriptomics reveals immunosuppressive niches and clonal diversity in extramedullary disease in multiple myeloma refractory to immunotherapy2025
  3. 3Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System Involvement2026
  4. 4Genomic and transcriptomic signatures of extramedullary multiple myeloma reveal possible drivers of therapeutic resistance2025
  5. 5Rare Locations of Plasma Cell Tumour: A Single-Centre Experience2025